SAMDaily.us | SRCSGT | B | Breast Cancer Metabolism in Association with Diabetes and Stress

SAMDAILY.US - ISSUE OF APRIL 08, 2020 SAM #6705
SOURCES SOUGHT

B -- Breast Cancer Metabolism in Association with Diabetes and Stress

Notice Date: 4/6/2020 7:36:18 AM
Notice Type: Sources Sought
NAICS: 334516 — Analytical Laboratory Instrument Manufacturing
Contracting Office: NIH NCI ROCKVILLE MD 20852 USA
ZIP Code: 20852
Solicitation Number: 75N91020R00025
Response Due: 4/15/2020 9:00:00 AM
Archive Date: 04/30/2020
Point of Contact: David Romley, Phone: 2402767822
E-Mail Address: David.Romley@nih.gov
(David.Romley@nih.gov)
Description: SOURCES SOUGHT NOTICE: Breast Cancer Metabolism in Association with Diabetes and Stress Notice Number: 75N91020R00025ï¿½ï¿½ Issued By: National Cancer Institute (NCI), Office of Acquisitions (OA) http://www.nci.nih.govï¿½ or http://rcb.cancer.gov/rcb-internet/ Key Dates: Capability Statement Due Date: April 15, 2020 by 12:00PM EST This Small Business Sources Sought Notice (SBSS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI). The purpose of this Sources Sought Notice is to identify qualified Small Business concerns including 8(a), HUBZone or Service-Disabled Veteran-owned businesses that are interested in and capable of performing the work described herein. The NCI does not intend to award a contract on the basis of responses received nor otherwise pay for the preparation of any information submitted. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This requirement is assigned North American Industry Classification System (NAICS) code 334516 with a size standard of 1000 employees. As a result of this Sources Sought Notice, the NCI may issue a Request for Quotation (RFQ). THERE IS NO SOLICITATION AVAILABLE AT THIS TIME.ï¿½ However, should such a requirement materialize, no basis for claims against NCI shall arise as a result of a response to this Sources Sought Notice or the NCIï¿½s use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. OBJECTIVE STUDY 1:ï¿½ A total of 66 fresh-frozen breast tissues/cell lines will be analyzed to examine how diabetes may affect the metabolism of human breast tumors. For this study, CCR grew human breast cancer cell lines in mice from closely related strains that have or do not have diabetes as a co-morbidity, allowing for the study of the effect of diabetes on metabolism and tumor biology in a controlled experimental setting. In addition, CCR will analyze human breast tumors and adjacent non-cancerous breast tissue from patients with diabetes. This study is a continuation of two previous projects with Metabolon in which CCR studied the metabolism of 1) breast tumors from patients with and without diabetes and 2) human breast cancer cell lines that grow in high versus low glucose cell culture medium to mimic the effects of diabetes. The goal of this study is to combine the analysis results from the two previous projects and this current study to obtain a more complete picture of how diabetes affects breast cancer in human patients and experimental models to obtain robust findings that are common to all datasets and best describe the diabetes-related breast cancer biology and how it may affect disease progression and response to current standard cancer therapy. Recent clinical studies showed that co-morbidities like diabetes affect breast cancer outcomes and can decrease patient survival, indicating that diabetes affects the metabolism of breast tissues. In an earlier analysis of our Maryland breast cancer patient cohort, CCR had found that women with a diabetes diagnosis have decreased breast cancer-specific survival and alteration in tumor metabolism indicating that diabetes affects tumor biology through metabolism. It is quite plausible that diabetes-induced changes in insulin signaling and metabolism worsen tumor biology, but these effects have not been previously investigated. With the current experiments, CCR will compare diabetes-related metabolic changes in breast cancer xenografts that grew in mammary fat pads of mice from closely related strains that have or do not have diabetes as a co-morbidity. STUDY 2: This study evaluates the role of environmentally-induced stress signaling and co-morbidities in breast cancer progression. CCR started projects studying the impact of stressful life events and diabetes on tumor biology, using one comprehensive approach to elucidate the effect of these exposures on breast cancer metabolism. In a clinical study, breast cancer patients who were scheduled for breast cancer surgery received a short survey evaluating their perceived stress and social isolation status. CCR also collected frozen tumor and adjacent normal breast tissue and blood samples from these patients to evaluate whether the breast tissue or the blood samples have a biological signature related to their perceived stress and social isolation status. CCR hypothesizes that patients with a high perceived stress exposure have a biological signature consistent with a more aggressive disease and poorer survival. The pilot study is designed to collect 100 tumor/normal pairs from consented patients with a completed survey. In the present study, CCR will analyze 42 breast tumors and 41 adjacent non-cancerous breast tissues from patients with stress exposure data. The contractor will also merge the new dataset with older datasets that CCR previously received from Metabolon. This is essential for this project. The contractor offers this service at no additional charges, allowing for comparison of diabetes study-related findings with stress study-related findings. SCOPE The Molecular Epidemiology Section will provide the contractor with 11-60 mg of frozen breast tissue. The tissues will first be pulverized, and then processed using methanol in water for the extraction of metabolites. The Contractor must run Ultraperformance Liquid Chromatography coupled to tandem Mass Spectrometry (UPLC-MS/MS) and also on Gas Chromatography coupled to Mass Spectrometry (GC-MS) on the extracted samples. Contractor will quantitatively measure metabolite abundance in tissue extracts and confirm metabolite identities with standards. The contractor must have access to a large in-house library of known and identified molecules, against which any detected metabolites in a sample can be compared. The contractor additionally must have the software that can deconvolute the metabolomics data in such way that they can cluster together fragments from the same molecule that will be reported as one metabolite rather as multiple metabolites when reported back in a data spreadsheet format. This function of the software will be to reduce the amount of noise that this type of data can carry with it. The Contractor will provide relative quantitation values for all the metabolites with confirmed identities but also unknowns. The identified metabolites will be confirmed against the Contractorï¿½s in-house generated authentic standard library that includes retention time, molecular weight (m/z), preferred adducts, and in-source fragments as well as their associated MS/MS spectra for all molecules in the library. The Contractor will provide spectra of standards for publication if requested. CONTRACT REQUIREMENTS/ AND PERSONNEL QUALIFICATIONS The contractor will be profiling the metabolome of 93 human fresh-frozen breast tissues, 40 Xenograft tissues and 16 cell line pellets. The contractor will receive the samples, process the samples, and measure metabolites in the extracts using state of the art mass spectrometry equipment. Contractor will measure at least 1000 metabolites across all major classes. Covered classes should include amino acids, carbohydrates, lipids, nucleotides, microbiota metabolism, energy, cofactors & vitamins, xenobiotics, and novel metabolites. This large number of metabolites is required. Otherwise our group cannot reliably deduce what metabolic processes are affected by diabetes in breast cancer biology.ï¿½ The contractor will identify and quantitate metabolites across all classes of metabolites with less than 5% process variability and will provide a report and datasheet back to the customer that contain QC measurements and the standardized relative abundance values of these metabolites for all 149 samples (for further analysis at the NCI). The contractor will also merge the new dataset with older datasets that we previously received from Metabolon. This is essential for this project. The contractor offers this service at no additional charges, allowing CCR to compare diabetes study-related findings with stress study-related findings. DELIVERABLES Data will be communicated in such a way that molecules detected in the tissues will be identified against an in-house library and will be sent in a report back to the Molecular Epidemiology Section, Laboratory of Human Carcinogenesis, in an Excel sheet for further analysis. Excel sheet will contain sample IDs and standardized relative abundance of the about 1000 metabolites for each sample. 1. A relative concentration profile of all structurally named small-molecule entities, which can include both endogenous compounds, xenobiotics, and their metabolites, extracted from the samples and detected by our HD4 Global Metabolomics platform (Excel file). 2. An outline of the analytical methods is provided in Appendix form (Word report). 3. Access to the MetaboLync Client Portal for downloading the study deliverables (Word report, Excel data file). Standard Turnaround Time 8 - 12 weeks from receipt of samples and necessary information. How to Submit a Response: Page Limitations: Interested qualified small business organizations should submit a tailored capability statement for this requirement not to exceed 10 single sided pages including all attachments, resumes, charts, etc. (single spaced, 12-point font minimum) that clearly details the ability to perform the requirements of the notice described above.ï¿½ All proprietary information should be marked as such.ï¿½ï¿½ Responses should include a minimum of a one page resume of the individuals meeting the requirements, and up to two pages demonstrating experience over the past two years meeting the requirements of this notice.ï¿½ Statements should also include an indication of current small business status; this indication should be clearly marked on the first page of your capability statement (preferable placed under the eligible small business concernï¿½s name and address).ï¿½ Responses will be reviewed only by NIH personnel and will be held in a confidential manner. Organizations shall demonstrate 1.) Technical Approach 2.) Personnel Requirements and Organizational Experience. ï¿½ Due Date:ï¿½ Capability statements are due no later than April 15, 2020 by 12:00PM EST Delivery Point: All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the unique specifications described herein.ï¿½ All questions must be in writing and emailed to David.Romley@nih.gov.ï¿½ A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government.ï¿½ Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.ï¿½ In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through sam.gov.ï¿½ No collect calls will be accepted.ï¿½Please reference number 75N91020R00025 on all correspondence. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organizationï¿½s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a RFQ may be published in Fed Biz Opps. However, responses to this notice will not be considered adequate responses to a solicitation(s). Point of Contact: Inquiries concerning this Notice may be direct to: David Romley at David.Romley@nih.gov. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation.
Web Link: SAM.gov Permalink
(https://beta.sam.gov/opp/75d66c2e3f9d427683cbc5273a59f7e7/view)
Place of Performance: Address: Morrisville, NC, USA; Country: USA
Record: SN05611931-F 20200408/200406230149 (samdaily.us)
Source: SAM.gov Link to This Notice
(may not be valid after Archive Date)

| FSG Index | This Issue's Index | Today's SAM Daily Index Page |

Loren Data's SAM Daily™

B -- Breast Cancer Metabolism in Association with Diabetes and Stress